Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003556 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Melanoma
A Phase 1 study of Melanoma (Skin), sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00003556: Completed Phase 1 study of Melanoma (Skin), sponsored by National Cancer Institute (NCI).
NCT00003556 is a Phase 1 study of Melanoma (Skin) that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants, below the 137-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003556, a Phase 1 study of Melanoma (Skin), has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of vaccine therapy in treating patients with melanoma that cannot be treated with surgery. Vaccines may make the body build an immune response that may kill tumor cells. Combining more than one vaccine may kill more tumor cells.
Conditions Studied
Interventions
- BIOLOGICAL ALVAC-hB7.1
- BIOLOGICAL canarypox-hIL-12 melanoma vaccine
Study Locations (1)
Alabama
- University of Alabama Comprehensive Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 1999-01 |
| Phase | Phase 1 |
What the finished NCT00003556 record still lists
NCT00003556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 137-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which ALVAC-hB7.1 is the first listed.
NCT00003556 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT00003556 about?
NCT00003556 is a clinical study titled "Vaccine Therapy in Treating Patients With Melanoma". Phase I trial to study the effectiveness of vaccine therapy in treating patients with melanoma that cannot be treated with surgery. Vaccines may make the body build an immune response that may kill tumor cells. Combining more than one vaccine may kill more tumor cells.
What is the current status of trial NCT00003556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 1999-01.
What conditions does trial NCT00003556 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00003556?
The interventions under investigation include: ALVAC-hB7.1 (BIOLOGICAL), canarypox-hIL-12 melanoma vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003556?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003556 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003556's enrollment target sits among peer trials
15 27th of 30 higher than 3 of 30 other Melanoma (Skin) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma (Skin) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia